MMP13 and breast cancer: In response to the AR agonist CI-4AS-1, the expression of miR-100 and miR-125 was significantly reduced in MDA-MB-453 breast cancer cells, leading to the increased expression of miR-100 and miR-125 target metalloprotease-13 (MMP13) [42].